64. M. A. Felmlee, W. Krzyzanski, B. L. Morse, M. E. Morris, Use of a
Local Sensitivity analysis to Inform Study Design Based on a Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid. AAPS J.
(2011).
63. R. Achuthanandam, D.
Makropoulos, L. Johns, A. Volk, K. Brosnan,
J. Lu, W. Krzyzanski, P. J. Bugelski, Pharmacodynamics of CNTO 530 and darbepoetin-α
in human TNF-a transgenic mice, a murine model of anemia of chronic
disease.
Pharmacology
and Pharmacy 2:17-30 (2011).
62. S. Ait-Oudhia, A.
Vermeulen, W. Krzyzanski, Non-linear mixed effects modeling of the
time-variant disposition of erythropoietin in anemic cancer patients. Biopharm. Drug Dispos. 32:1-15 (2011).
61.
W. Krzyzanski, Interpretation of transit
compartments pharmacodynamic models as lifespan
based indirect response models. J. Pharmacokinet. Pharmacodyn. 38:179-204
(2011).
60. Y-M. Wang, W. Krzyzanski, S. Doshi, J. J. Xiao, J. J. Perez Ruixo, A. T. Chow, Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 12:729-740
(2010).
59. J.J. Xiao, W. Krzyzanski, Y-M.
Wang, H. Li, M. J. Rose, M. Ma, Y. Wu, B. Hinkle, J. J. Perez-Ruixo, Pharmacokinetics of anti-hepcidin
monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J.
12:646-657 (2010).
58. W. Krzyzanski, P. Wiczling, P. Lowe, E. Pigeolet, M. Fink, A. Berghout, S.
Balser, Population modeling of filgrastim PK-PD
in healthy adults following intravenous and subcutaneous administrations. J.
Clin. Pharmacol. 50:101S-112S
(2010).
57.
S. Ait-Oudhia,
J-M. Scherrmann, W. Krzyzanski,
Simultaneous
pharmacokinetics/pharmacodynamics modeling of recombinant human
erythropoietin upon multiple intravenous dosing in rats. JPET 334:897�910
(2010).
56. S. Ait-Oudhia, J-M. Scherrmann, W.
Krzyzanski, Time-dependent clearance and hematological pharmacodynamics upon
erythropoietin multiple dosing in rats. Biopharm. Drug Dispos. (2010).
55. X. Yan, D. E. Mager, W. Krzyzanski,
Selection between Michaelis-Menten and
target-mediated drug disposition pharmacokinetic models. J.
Pharmacokinet. Pharmacodyn. 37:25-48 (2010).
54. L. A. Khinkis, W. Krzyzanski, W. J.
Jusko, W. R. Greco, D-optimal designs for parameter
estimation for indirect pharmacodynamic response
models. J. Pharmacokinet. Pharmacodyn.
36:523-539 (2009).
53.
P. Wiczling, P. Lowe, E. Pigeolet, F. Ludicke, S. Balser, W. Krzyzanski,
Population pharmacokinetic modelling of filgrastim in healthy adults following
intravenous and subcutaneous administrations. Clin.
Pharmacokinet.
48:817-826 (2009)
52.
J. J. Perez-Ruixo,
W. Krzyzanski, E. Bouman-Thio, B. Miller, H. Jang, S. A. Bai,
H. Zhou, J. Yohrling, A. Cohen, J. Burggraaf,
K. Franson, H. Davis, Pharmacokinetics and
pharmacodynamics of the erythropoietin mimetibody
construct CNTO 528in
healthy subjects. Clin. Pharmacokinet. 48:601-613
(2009).
51. P. Wiczling, S.
Ait-Oudhia, W. Krzyzanski, Flow
cytometric analysis of reticulocyte
maturation after erythropoietin administration in rats. Cytometry Part A 75A:584-592 (2009).
50. A. Marathe, W.
Krzyzanski, D. E. Mager,
Numerical validation and properties of a rapid binding approximation of a
target-mediated drug disposition pharmacokinetic model. J. Pharmacokinet. Pharmacodyn. 36:199-219
(2009).
49. W. Krzyzanski,
J. J. Perez-Ruixo, A. Vermeulen, Basic pharmacodynamic models for agents that alter the lifespan
distribution of natural cells. J. Pharmacokinet.
Pharmacodyn.
35:349-377 (2008).
48. M. Danielewski,
K. Holly, W. Krzyzanski, Interdiffusion in r-component (r �
2) one dimensional mixture showing constant concentration, Computer Methods in
Materials Science 8:31-46 (2008).
47. J. J. Perez-Ruixo, W. Krzyzanski, J. Hing, Pharmacodynamic analysis
of recombinant human erythropoietin effect on reticulocyte production rate and
age distribution in healthy subjects. Clin. Pharmacokinet. 47:399-415
(2008).
46. S. Woo, W. Krzyzanski,
W. J. Jusko, Pharmacodynamic model for chemotherapy induced anemia in
rats. Cancer Chemother. Pharmacol. 62:123-133
(2008).
45. S. Woo, W. Krzyzanski, A.-M. Duliege, R.
B. Stead, W. J. Jusko, Population pharmacokinetics
and pharmacodynamics of peptidic erythropoiesis
receptor agonist (ERA) in healthy volunteers. J. Clin. Pharmacol. (2008).
44. P. Wiczling, W. Krzyzanski, Flow
cytometric assessment of homeostatic aging of
reticulocytes in rats. Exp. Hematol. 36:119-127
(2008).
43.
W.
Krzyzanski, E. Wyska,
Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy
volunteers. Naunyn-Schmiedeberg�s Arch.
Pharmacol. 377:637-645 (2008).
42.
S. Woo, W. Krzyzanski, W. J. Jusko,
Target-mediated pharmacokinetic and pharmacodynamic
model of recombinant human erythropoietin (rHuEPO).
J. Pharmacokinet. Pharmacodyn. 34:849-868 (2007).
41.
A. K. Abraham, W. Krzyzanski, D. E. Mager, Partial derivative-based sensitivity analysis of
models describing target-mediated drug disposition, The AAPS J. 9 Article 20
(2007) (http://www.aapsj.org).
40.
P. Wiczling, W. Krzyzanski, Method of determination of the reticulocyte
age distribution from flow cytometry count by a
structured-population model. Cytometry Part A
71A:460-67 (2007).
39.
W. Krzyzanski, J. Oberdoester, R. R. Rabin, Mechanism of ethanol enhancement
of apoptosis and caspase activation in
serum-deprived PC12 cells. Life Sciences 81:756-764 (2007).
38.
R. M. Straubinger, W. Krzyzanski, C. M. Francoforte,
J. Qu, Applications of quantitative pharmacodynamic
effect markers in drug target identification and therapy development. Anticancer
Res. 27:1237-46 (2007).
37.
W. Krzyzanski, J. Bell, Modelling the geometric features and investigating
electrical properties of dendrites in a fish thalamic neuron. Math.
Med. Biol. 24: 271-286 (2007).
36. W. Krzyzanski, J. J. Perez-Ruixo,
An assessment of recombinant human erythropoietin effect on reticulocyte
production rate and lifespan distribution in healthy subjects. Pharm. Res.
24:758-771 (2007).
35. A. Hazra, W. Krzyzanski, W.J.
Jusko, Mathematical assessment of properties of
precursor-dependent indirect pharmacodynamic
response models. J. Pharmacokin. Pharmacodyn. 33:683-717
(2006).
34.
S. Woo, W. Krzyzanski, W. J. Jusko,
Pharmacokinetic and pharmacodynamic modeling of
recombinant human erythropoietin after intravenous and subcutaneous
administration in rats. J. Pharmacol. Exp. Ther. 319:1297-06
(2006).
33.
W. Krzyzanski, J. Dmochowski, N. Matsushima, W. J. Jusko, Assessment of dosing impact on intra-individual
variability in estimation of parameters for basic indirect response models.
J. Pharmacokin. Pharmacodyn.
33:635-655 (2006).
32. Z. Yao, W. Krzyzanski,
W. J. Jusko, Assessment of basic indirect pharmacodynamic response models with physiological limits.
J. Pharmacokin. Pharmacodyn. 33:167-193
(2006).
31. W. Krzyzanski, S. Woo, W. J. Jusko, Pharmacodynamic models
for agents that alter production of natural cells with various distributions of
lifespans. J. Pharmacokin. Pharmacodyn. 33:125-165 (2006).
30.
N. M. Jamal, W. Krzyzanski, W. Cheung, C. Y.
Lau, and H. A. Messner, Evaluation of epoetin
alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation
(BFU-E) in culture. J. Int. Med. Res. 34:42-51 (2006).
29. J. J. Perez-Ruixo, H. C. Kimko, A. C.
Chow, V. Piotrovsky, W. Krzyzanski, and W. J. Jusko,
Population cell lifespan models for effects of drugs following indirect
mechanism of action. J. Pharmacokin. Pharmacodyn. 32: 767-793
(2005).
28. D. E. Mager
and W. Krzyzanski, Quasi-equilibrium pharmcokinetic
model for drugs exhibiting target-mediated drug disposition. Pharm. Res.
22: 1589-96 (2005).
27. W. Krzyzanski, W. J. Jusko, M. C. Wacholtz, N. Minton, W. K. Cheung, Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur. J. Pharm. Sci. 26:295-306
(2005).
26.
J. Earp, W. Krzyzanski, A. Chakraborty,
M. K. Zamacona, W. J. Jusko, Assassment of drug
interactions relevant to pharmcodynamic indirect
response models. J. Pharmcokin. Pharmacodyn. 31:345-380 (2004).
25. F. Jin and W. Krzyzanski, Pharmacokinetic model of target-mediated
disposition of thombopoietin, AAPS PharmSci
6: Article 9 (2004).
24. E. Wyska, D. E. Mager, W. Krzyzanski, Methods of estimation IC50 and
SC50 parameters for indirect response models from single dose data,
J. Pharm. Sci. 92: 1438-54 (2003).
23. W. Krzyzanski, J. Bell, R. R. Poznanski, Neuronal integrative analysis of the �dumbbell�
model for passive neurons, J. Integr. Neurosci. 1: 217-239 (2002).
22. S.
H. Bernstein, W. J. Jusko, W. Krzyzanski, J. Nichol and M. Wetzler, Pharmacodynamic
modeling of thrombopoietin, platelet and
megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose
intensive chemotherapy, J.
Clin.Pharmacol. 42: 501-11
(2002).
21. W. Krzyzanski and W. J. Jusko,
Multiple-pool cell lifespan model of hematologic effects of anticancer agents,
J. Pharmacokin. Pharmacodyn., 29:311-337
(2002).
20.
I. Perlstein, D. Stepansky, W.
Krzyzanski, and A. Hofman, A signal transduction pharmacodynamic model of the kinetics of parasympathomimetic
activity of low-dose scopolamine and atropine in rats. J. Pharm. Sci. 91:
2500-10 (2002).
19. W. Krzyzanski, An application of a weak solution of the cable
equation to the Rall model of a nerve cell, IMA J.
Math. Appl. Med. Biol., 18: 377-407 (2001).
18. T. A. Puchalski, W. Krzyzanski, and
W. J. Jusko, Pharmacodynamic modeling of lansoprazole using an indirect irreversible response
model, J. Clin. Pharmacol.,
41: 251-258 (2001).
17. W. Krzyzanski and W. J. Jusko,
Indirect pharmacodynamic models for responses with
multicompartmental distribution or polyexponential
disposition, J. Pharmacokin. Pharmacodyn., 28:
57-78 (2001).
16. W. Krzyzanski, Asymptotics of the
total net direct effect for large drug doses, J. Math. Biol., 41: 477-492
(2000).
15. W. Krzyzanski, A. Chakraborty,
and W. J. Jusko, Algorithm for application of
Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models, Chronobiol.
Int., 17: 77-94
(2000).
14. M. Danielewski, W. Krzyzanski,
and R. Bachorczyk, Generalized Darken�s Method; from Diffusional Structures to Nonparabolic Diffusion. Solid State Phenomena 72:
141-152 (2000).
13. W. Krzyzanski, R. Ramakrishnan,
and W. J. Jusko, Basic models for agents that alter
production of natural cells, J. Pharmacokin.
Biopharm.,
27: 467-489 (1999).
12. W. Krzyzanski and J. Bell, Analysis of a model of membrane
potential for a skin mechanoreceptor, Math. Biosci. 158: 1-45 (1999).
11. A. Chakraborty, W. Krzyzanski,
and W. J. Jusko, Mathematical modeling of circadian
cortisol concentrations in indirect response models, J. Pharmacokin. Biopharm., 27: 23-43
(1999).
10. M. Danielewski, W. Krzyzanski, B.
Figura, P. Kita, G. Pecak, The non-reduced solution of the Fisher model, grain
boundary diffusion in R3, Metallofiz.
Noveishie Tekhnol. 21:
55-60 (1999).
9. W. Krzyzanski and W. J. Jusko,
Caution in use of empirical equations for pharmacodynamic indirect response models, J. Pharmacokin.
Biopharm.,
26: 735-741 (1998).
8. W. Krzyzanski and W. J. Jusko,
Characterization of pharmacodynamic recession slopes
for direct and indirect response models, J. Pharmacokin. Biopharm. 26: 409-436
(1998).
7. W. Krzyzanski and W. J. Jusko,
Mathematical
formalism and characteristics of four
basic models of indirect pharmacodynamic
responses for drug infusions, J. Pharmacokin. Biopharm. 26: 385-408 (1998).
6. W. Krzyzanski and W. J. Jusko,
Integrated functions for four basic models of indirect pharmacodynamic response, J. Pharm. Sci. 87: 67-72
(1998).
5. W. Krzyzanski and W. J. Jusko,
Mathematical formalism for the properties of four basic models of indirect
pharmacodynamic responses, J. Pharmacokin. Biopharm. 25: 107-123 (1997).
4. W. Krzyzanski and W. J. Jusko,
Application of moment analysis to the sigmoid effect model for drug administered
intravenously, Pharm. Res. 14: 949-952 (1997).
3. M. Danielewski and W. Krzyzanski,
Momentum and energy in open systems, Phys. Stat. Sol. (a) 145: 351-361
(1994).
2. M. Danielewski, K. Holly, and W. Krzyzanski, Interdiffusion in r-component (r�2)
one dimensional mixture showing constant concentration, Polish J. Chem. 68:
2031-47 (1994).
1.
W. Krzyzanski, Expansion of the solution of
the Neumann problem for the Poisson equation into the Fourier series with
respect to eigenfunctions of this problem. Universitatis Iagellonicae
Acta Mathematica 30:
199-213 (1993).